RBC Europe’s Charles River Laboratories CRL Stock Holding History

RBC Europe’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$43K	Hold	202	–	–	﹤0.01%	340
2022 Q1	$57K	Sell	202 -18	-8%	-$5.55K	﹤0.01%	332
2021 Q4	$83K	Hold	220	–	–	﹤0.01%	301
2021 Q3	$90.8K	Hold	220	–	–	﹤0.01%	438
2021 Q2	$81.4K	Hold	220	–	–	﹤0.01%	474
2021 Q1	$63.8K	Hold	220	–	–	﹤0.01%	501
2020 Q4	$55K	Hold	220	–	–	﹤0.01%	496
2020 Q3	$49.8K	Hold	220	–	–	﹤0.01%	459
2020 Q2	$38.4K	Hold	220	–	–	﹤0.01%	498
2020 Q1	$27.8K	Hold	220	–	–	﹤0.01%	489
2019 Q4	$33.6K	Hold	220	–	–	﹤0.01%	544
2019 Q3	$29.1K	Hold	220	–	–	﹤0.01%	551
2019 Q2	$31.2K	Hold	220	–	–	﹤0.01%	561
2019 Q1	$32K	Hold	220	–	–	﹤0.01%	558
2018 Q4	$24.9K	Hold	220	–	–	﹤0.01%	588
2018 Q3	$29.6K	Hold	220	–	–	﹤0.01%	595
2018 Q2	$24.7K	Hold	220	–	–	﹤0.01%	629
2018 Q1	$23.5K	Hold	220	–	–	﹤0.01%	643
2017 Q4	$24.1K	Hold	220	–	–	﹤0.01%	634
2017 Q3	$23.8K	Buy	+220	New	+$22.6K	﹤0.01%	647

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBC Europe's CRL Position: Q2 2022 in Review

RBC Europe held its Charles River Laboratories (CRL) position steady in Q2 2022 at 202 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

RBC Europe first reported a position in CRL in Q3 2017 and has held it in 20 quarters since. The position peaked at $90.8K in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

RBC Europe held 202 shares of Charles River Laboratories worth $43K as of Q2 2022.
RBC Europe left its Charles River Laboratories share count unchanged in Q2 2022.
Charles River Laboratories made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #340 holding.
RBC Europe first reported a position in Charles River Laboratories in Q3 2017 and has held it in 20 quarters since.
RBC Europe's Charles River Laboratories position peaked at $90.8K in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.